BioLife Solutions (NASDAQ:BLFS) CFO Sells $25,959.29 in Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) CFO Troy Wichterman sold 1,033 shares of the company’s stock in a transaction on Tuesday, December 9th. The shares were sold at an average price of $25.13, for a total transaction of $25,959.29. Following the sale, the chief financial officer owned 151,736 shares of the company’s stock, valued at $3,813,125.68. This represents a 0.68% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Troy Wichterman also recently made the following trade(s):

• On Thursday, December 4th, Troy Wichterman sold 30,000 shares of BioLife Solutions stock. The shares were sold at an average price of $25.72, for a total transaction of $771,600.00.
• On Tuesday, November 25th, Troy Wichterman sold 584 shares of BioLife Solutions stock. The stock was sold at an average price of $26.74, for a total value of $15,616.16.
• On Thursday, October 9th, Troy Wichterman sold 833 shares of BioLife Solutions stock. The shares were sold at an average price of $27.36, for a total value of $22,790.88.

BioLife Solutions Price Performance

BLFS opened at $25.07 on Friday. BioLife Solutions, Inc. has a one year low of $19.10 and a one year high of $29.62. The business has a 50 day simple moving average of $26.26 and a two-hundred day simple moving average of $24.55. The firm has a market capitalization of $1.21 billion, a price-to-earnings ratio of -358.09 and a beta of 1.93.

Institutional Trading of BioLife Solutions

A number of large investors have recently added to or reduced their stakes in the company. Hantz Financial Services Inc. increased its holdings in shares of BioLife Solutions by 54.1% in the 3rd quarter. Hantz Financial Services Inc. now owns 1,877 shares of the medical equipment provider’s stock worth $48,000 after buying an additional 659 shares during the last quarter. State of Wyoming lifted its position in shares of BioLife Solutions by 353.1% during the first quarter. State of Wyoming now owns 1,912 shares of the medical equipment provider’s stock worth $44,000 after purchasing an additional 1,490 shares during the last quarter. Quarry LP lifted its holdings in BioLife Solutions by 50.9% during the 3rd quarter. Quarry LP now owns 2,113 shares of the medical equipment provider’s stock valued at $54,000 after buying an additional 713 shares in the last quarter. US Bancorp DE boosted its holdings in shares of BioLife Solutions by 243.7% in the first quarter. US Bancorp DE now owns 2,155 shares of the medical equipment provider’s stock valued at $49,000 after purchasing an additional 1,528 shares during the period. Finally, Ameritas Investment Partners Inc. lifted its holdings in shares of BioLife Solutions by 12.8% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,873 shares of the medical equipment provider’s stock worth $83,000 after buying an additional 441 shares during the period. Institutional investors own 93.24% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on BLFS shares. Zacks Research cut shares of BioLife Solutions from a “strong-buy” rating to a “hold” rating in a report on Monday, December 8th. Wall Street Zen lowered shares of BioLife Solutions from a “buy” rating to a “hold” rating in a research note on Sunday, November 30th. Weiss Ratings reiterated a “sell (d-)” rating on shares of BioLife Solutions in a research note on Wednesday, October 8th. Finally, HC Wainwright reiterated a “buy” rating and set a $32.00 target price on shares of BioLife Solutions in a research report on Monday, November 24th. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $31.00.

About BioLife Solutions

BioLife Solutions (NASDAQ:BLFS) specializes in biopreservation and cold chain workflow solutions for cell and gene therapies, regenerative medicine and other advanced biologics. The company develops and markets proprietary cryopreservation media and technology platforms designed to maintain cell viability and functionality during processing, storage and transport. BioLife’s product portfolio addresses critical steps in the manufacturing and distribution of cell-based products, helping life science researchers and biopharmaceutical manufacturers protect and preserve living cells.

The company’s flagship offerings include CryoStor, a family of serum-free cryopreservation media; HypoThermosol, a hypothermic storage solution for short-term cell and tissue preservation; and the ThawSTAR system, an automated cell thawing instrument that delivers controlled and reproducible warming of frozen cell therapies.